BackNgm Biopharmaceuticals Overview

Ngm Biopharmaceuticals Receivables

Track Ngm Biopharmaceuticals's receivables ($58K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$58000.00
99.23% YoYΔ $-7.52M vs prior year quarter

Peer trimmed avg / median

Loading

Ngm Biopharmaceuticals Receivables History

Loading

Ngm Biopharmaceuticals vs. peers: Receivables Comparison

Loading

Ngm Biopharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ngm Biopharmaceuticals (NGM) FAQ

As of the most recent data (December 2023), NGM shows a receivables of $58K. That compares with $7.6M in the prior-year period — down 99.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NGM's receivables is now $58K (was $7.6M) — a 99.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Ngm Biopharmaceuticals is outperforming or lagging.

Tracking NGM's receivables over time shows whether Ngm Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $58K That compares with $7.6M in the prior-year period — down 99.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Ngm Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $58K) with ownership activity and broader fundamentals.

Ngm Biopharmaceuticals's receivables is $58K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.